REDHILL BIOPHARMA LTD. Expense From Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets
REDHILL BIOPHARMA LTD. (RDHL) reported Expense From Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets of $5.67 million for the 12-month period ending 2022-12-31, per its 20-F filed 2023-04-28.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets · last filed 2023-04-28
- REDHILL BIOPHARMA LTD. expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets for the quarter ending 2022-06-30 was $618.00K, a 88.28% decline year-over-year.
- REDHILL BIOPHARMA LTD. expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets for the quarter ending 2021-06-30 was $5.27M.
| Period end | Expense From Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 3 month | Expense From Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 6 month | Expense From Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 12 month |
|---|---|---|---|
| 2022-12-31 | $5.67M 20-F · filed 2023-04-28 | ||
| 2022-06-30 | $618.00K 6-K · filed 2022-11-07 | $2.92M 6-K · filed 2022-11-07 | |
| 2021-12-31 | $10.21M 20-F · filed 2023-04-28 | ||
| 2021-06-30 | $5.27M 6-K · filed 2022-11-07 | $6.15M 6-K · filed 2022-11-07 | |
| 2020-12-31 | $4.20M 20-F · filed 2023-04-28 | ||
| 2019-12-31 | $3.03M 20-F · filed 2022-03-17 |